-
Views
-
Cite
Cite
Sigrid Jehle, Henry N. Hulter, Reto Krapf, Effect of Potassium Citrate on Bone Density, Microarchitecture, and Fracture Risk in Healthy Older Adults without Osteoporosis: A Randomized Controlled Trial, The Journal of Clinical Endocrinology & Metabolism, Volume 98, Issue 1, 1 January 2013, Pages 207–217, https://doi.org/10.1210/jc.2012-3099
Close - Share Icon Share
Abstract
The acid load imposed by a modern diet may play an important role in the pathophysiology of osteoporosis.
Our objective was to evaluate the skeletal efficacy and safety and the effect on fracture prediction of K-citrate to neutralize diet-induced acid loads.
We conducted a randomized, double-blind, placebo-controlled trial at a teaching hospital.
Subjects included 201 elderly (>65 yr old) healthy men and women (t-score of −0.6 at lumbar spine).
Intervention was 60 mEq of K-citrate daily or placebo by mouth. All subjects received calcium and vitamin D.
The primary outcome was change in areal bone mineral density (aBMD) at the lumbar spine by dual-energy x-ray absorptiometry after 24 months. Secondary endpoints included changes in volumetric density and microarchitectural parameters by high-resolution peripheral quantitative computed tomography in both radii and both tibiae and fracture risk assessment by FRAX (Switzerland).
K-citrate increased aBMD at lumbar spine from baseline by 1.7 ± 1.5% [95% confidence interval (CI) = 1.0–2.3, P < 0.001] net of placebo after 24 months. High-resolution peripheral quantitative computed tomography-measured trabecular densities increased at nondominant tibia (1.3 ± 1.3%, CI = 0.7–1.9, P < 0.001) and nondominant radius (2.0 ± 2.0%, CI = 1.4–2.7, P < 0.001). At nondominant radius, trabecular bone volume/tissue volume increased by 0.9 ± 0.8%, (CI = 0.1–1.7), trabecular thickness by 1.5 ± 1.6% (CI = 0.7–2.3), and trabecular number by 1.9 ± 1.8% (CI = 0.7–3.1, for all, P < 0.05). K-citrate diminished fracture prediction score by FRAX significantly in both sexes.
Among a group of healthy elderly persons without osteoporosis, treatment with K-citrate for 24 months resulted in a significant increase in aBMD and volumetric BMD at several sites tested, while also improving bone microarchitecture. Based on the effect on fracture prediction, an effect on future fractures by K-citrate is possible.
